Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Valia22-11-2017
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha ValiaSun Pharma net dips by 59% in Q2, US sales down by 47%
Sun Pharmaceutical Industries has received major setback due to lower sales in US during the second quarter ended September 2017.Sun Pharma: Light at the end of the tunnel
Focus on developing specialty business will prop up growthSun Pharma shares dip 4%; market cap drops by Rs 5,065 cr on Q2 numbers
Shares of Sun Pharmaceutical Industries today ended 4 per cent lower after the company reported a 59.19 per cent decline in consolidated net profit for the September quarter of the current fiscal....Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha ValiaScheme of Arrangement
Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding Scheme of Arrangement approved at Board Meeting held on November 14, 2017Outcome of Committee Meeting
This is to inform you that the Committee of Directors (Allotment) at its meeting held today i.e. on Tuesday, November 14, 2017 allotted 1,260 (One Thousand Two Hundred and Sixty) equity shares of the Company of Re 1/- each, on exercise of stock options under the SUN Employee Stock Option Scheme -2015. Accordingly, post the above allotment the paid-up equity share capital of the Company is Rs. 2,39,93,09,346/- (Rupees Two Hundred and Thirty...Sun Pharma: Taro provides some respite
Key triggers are in improvement in ex-Taro performance, resolution of US FDA issuesDisclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Valia